# Admin-Core-001

> **NIH NIH U54** · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2022 · $225,752

## Abstract

This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to further enable adaptive/hybrid immune approaches

## Key facts

- **NIH application ID:** 10707766
- **Project number:** 3U54CA232561-01A1S4
- **Recipient organization:** RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- **Principal Investigator:** TIMOTHY P CRIPE
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $225,752
- **Award type:** 3
- **Project period:** 2022-04-18 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10707766

## Citation

> US National Institutes of Health, RePORTER application 10707766, Admin-Core-001 (3U54CA232561-01A1S4). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10707766. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*